Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:JAGX NASDAQ:PTPI NASDAQ:REVB NASDAQ:VRAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJAGXJaguar Animal Health$2.14+1.9%$2.77$1.93▼$35.25$4.02M0.4396,659 shs49,984 shsPTPIPetros Pharmaceuticals$0.03-8.8%$0.03$0.02▼$16.25$844K1.565.29 million shs909,932 shsREVBRevelation Biosciences$2.38-6.7%$2.58$2.11▼$168.00$3.91M-0.06222,746 shs206,164 shsVRAXVirax Biolabs Group$0.79-0.5%$0.89$0.74▼$9.00$3.43M1.66189,447 shs22,274 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJAGXJaguar Animal Health+1.90%+8.08%-18.63%-74.85%-92.00%PTPIPetros Pharmaceuticals-4.24%-16.36%-3.21%-77.77%-99.68%REVBRevelation Biosciences-6.67%-2.46%-16.49%-75.05%-95.32%VRAXVirax Biolabs Group-0.38%-7.00%-14.90%-25.14%-27.89%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationJAGXJaguar Animal Health1.8261 of 5 stars3.53.00.00.01.10.00.6PTPIPetros PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AREVBRevelation Biosciences0.4027 of 5 stars0.02.00.00.01.50.01.3VRAXVirax Biolabs Group3.1325 of 5 stars3.55.00.00.00.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJAGXJaguar Animal Health 3.00Buy$60.002,703.74% UpsidePTPIPetros Pharmaceuticals 0.00N/AN/AN/AREVBRevelation Biosciences 0.00N/AN/AN/AVRAXVirax Biolabs Group 3.00Buy$3.00281.68% UpsideCurrent Analyst Ratings BreakdownLatest PTPI, JAGX, REVB, and VRAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025JAGXJaguar Animal HealthFirst BerlinSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.00(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJAGXJaguar Animal Health$11.69M0.35N/AN/A$12.29 per share0.17PTPIPetros Pharmaceuticals$5.11M0.17N/AN/A$4.04 per share0.01REVBRevelation BiosciencesN/AN/AN/AN/A$27.05 per shareN/AVRAXVirax Biolabs Group$10K341.12N/AN/A$1.26 per share0.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJAGXJaguar Animal Health-$38.49MN/A0.00N/AN/A-343.92%-432.91%-71.25%8/12/2025 (Estimated)PTPIPetros Pharmaceuticals-$8.16M-$60.87N/A∞N/AN/A-78.22%-23.50%N/AREVBRevelation Biosciences-$15.04M-$307.86N/AN/AN/AN/A-299.46%-115.36%N/AVRAXVirax Biolabs Group-$6.06MN/A0.00∞N/AN/AN/AN/AN/ALatest PTPI, JAGX, REVB, and VRAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025JAGXJaguar Animal Health-$7.13N/AN/AN/A$3.27 millionN/A5/15/2025Q1 2025JAGXJaguar Animal Health-$18.50-$16.70+$1.80-$16.70$3.29 million$3.50 million5/15/2025Q1 2025PTPIPetros PharmaceuticalsN/A-$8.46N/A-$9.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthJAGXJaguar Animal HealthN/AN/AN/AN/AN/APTPIPetros PharmaceuticalsN/AN/AN/AN/AN/AREVBRevelation BiosciencesN/AN/AN/AN/AN/AVRAXVirax Biolabs GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJAGXJaguar Animal Health22.201.080.70PTPIPetros Pharmaceuticals1.580.850.74REVBRevelation BiosciencesN/A3.603.60VRAXVirax Biolabs GroupN/A7.277.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJAGXJaguar Animal Health12.04%PTPIPetros Pharmaceuticals12.34%REVBRevelation Biosciences12.80%VRAXVirax Biolabs Group8.61%Insider OwnershipCompanyInsider OwnershipJAGXJaguar Animal Health4.55%PTPIPetros Pharmaceuticals12.25%REVBRevelation Biosciences2.30%VRAXVirax Biolabs Group45.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableJAGXJaguar Animal Health501.91 million1.83 millionNo DataPTPIPetros Pharmaceuticals2031.16 million9.93 millionNot OptionableREVBRevelation Biosciences101.53 million1.50 millionNot OptionableVRAXVirax Biolabs Group54.34 million2.38 millionNot OptionablePTPI, JAGX, REVB, and VRAX HeadlinesRecent News About These CompaniesVirax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial StrategyJuly 29, 2025 | prnewswire.comVirax Biolabs Group Limited (VRAX) Latest Stock News & Headlines ...July 22, 2025 | finance.yahoo.comVirax BioLabs Group Limited: Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price DeficiencyJuly 20, 2025 | finanznachrichten.deVirax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price DeficiencyJuly 18, 2025 | prnewswire.comHC Wainwright & Co. Initiates Coverage of Virax Biolabs Group (VRAX) with Buy RecommendationMarch 31, 2025 | msn.comVirax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy RatingMarch 31, 2025 | benzinga.comVirax Biolabs Launches Clinical Study on T Cell DysfunctionMarch 18, 2025 | msn.comVirax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection SyndromesMarch 18, 2025 | prnewswire.comVirax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation MeetingMarch 13, 2025 | prnewswire.comVirax Biolabs to Present at 19th World Immune Regulation MeetingMarch 5, 2025 | prnewswire.comVirax Biolabs Aligns with US Health Department on Vaccine TransparencyFebruary 25, 2025 | tipranks.comVirax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine EfficacyFebruary 25, 2025 | prnewswire.comCosmos Health expands distribution of Avian Influenza kitsJanuary 23, 2025 | msn.comCosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and KuwaitJanuary 23, 2025 | accessnewswire.comACosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC CountriesJanuary 13, 2025 | accesswire.comAVirax Biolabs Group Ltd (VRAX) Stock: Beyond the Surface of Its Performance?December 19, 2024 | bovnews.comBVirax Biolabs Announces Strategic Goals and Developments for 2025December 18, 2024 | markets.businessinsider.comVirax Biolabs' CEO James Foster Issues Letter to ShareholdersDecember 17, 2024 | prnewswire.comVirax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and SwitzerlandDecember 10, 2024 | prnewswire.comVirax Biolabs Sees Asset Growth Amid Financial LossNovember 22, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePTPI, JAGX, REVB, and VRAX Company DescriptionsJaguar Animal Health NASDAQ:JAGX$2.14 +0.04 (+1.90%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$2.15 +0.01 (+0.42%) As of 08/8/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.Petros Pharmaceuticals NASDAQ:PTPI$0.03 0.00 (-8.75%) As of 08/8/2025 03:59 PM EasternPetros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.Revelation Biosciences NASDAQ:REVB$2.38 -0.17 (-6.67%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$2.44 +0.06 (+2.48%) As of 08/8/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.Virax Biolabs Group NASDAQ:VRAX$0.79 0.00 (-0.52%) Closing price 08/8/2025 03:53 PM EasternExtended Trading$0.79 0.00 (0.00%) As of 08/8/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down DraftKings Posts Record Quarter, Eyes Profitability Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
